Q4/2024 & FY2024 Results

JP

Another year has passed and it was a source of multiple déjà-vu moments: Russia did what Russia typically does, war in Ukraine is still raging on but perhaps next year will some kind of change to this, and Trump won the US presidential elections. China is also doing its best to reach the stupidity levels of Russia and North Korea is definitely there already. Next year will be full of challenges in many fronts but perhaps we will see also many positive developments.

Looking at the portfolio both 4th quarter and whole year were quite ok: main portfolio dropped 0,92% during Q4 but gained 11,95% during FY2o24. Dividend income during the year was 11571 EUR before taxes. This covered 123,29% of base consumption. Projected dividends for next year are sitting at 13200 EUR with current portfolio. One final step to go and that would be the step to actually living off dividends. Not nececcasarily solely off dividends but without fixed full time job. Remains to be seen when time is ripe for that and how exactly I’ll execute that transition.

Strategy for next year will not have any major changes: I’ll probably add on few pharma stocks, possibly on Nordea Bank and might even add new position on dividend style ETF despite those being slightly less tax efficient – or should I say more inefficient – than direct positions on stocks. One decision to make is the potential restoring of Capman position, and I have also been comtemplating new positions on Valmet and Orthex. Let’s see how valuations change during the year.

Recent (Short Term?) Swap: Capman Oyj for Fortum Oyj

JP

End of the year cleanups continued. I sold all 3000 shares of Capman Oyj for 1,70 EUR per share and bought additional 300 shares of Fortum Oyj for 13,00 EUR per share. It remains to be seen if this Capman exit is only a short term move. This is now mostly tax related move: I record minor losses and I suspect that the stock might drop further down as people might be making similar moves before the year ends. I have very mixed feeling about Capman as it’s a poor performer on my portfolio and I have already significant exposure in the sector itself without it. Then again valuation can be considered to be relatively cheap and there has been some insider activity. But, there’s a bold question mark next to this assumption. Need to think about it, might buy these back or might not.

Recent Swap: Hennes & Mauritz AB for Nordea Bank Abp and Pfizer Inc. , Recent Buy: Kesko Oyj (B)

JP

Year is coming to an end and it’s time to do some cleanups in the portfolio. Hennes & Mauritz has been the performing very poorly for quite some time now. I initially had anticipated a rebound on execution possibly combined with a buyout since ownership is heavily in the hands of Persson family. Neither of these really materialised and – as the sector in general is and has been chronically troubled – it’s time to move on. I sold all 250 shares 155,35 SEK per share and bought additional 200 shares of Nordea Bank Abp and additional 40 shares of Pfizer Inc. for 25,58 USD per share. For now I consider this Pfizer position to be full but might consider increasing it should market overreactions provide meaningful possibilities.

In addition to this swap I bought additional 25 shares of Kesko (B series) for 18,615 EUR per share. Kesko was down today after reporting somewhat disappointing numbers and this purchase was anyway preplanned for December. This completes my Kesko position at least for the short term. Position consists of 300 shares and I’ll probably increase the position only under extra special circumstances.

Recent Buy: Pfizer Inc.

JP

Black friday is here and Nordnet had a campaign for US stocks without transactions fees. This enabled me to re-invest accumulated dollar dividends with a purchase of additional 30 shares of Pfizer Inc. bought for 25,80 USD per share. To me Pfizer has looked cheap for quite some time now. Even more so after Trump’s election win which was followed with nominations that might be negative for big pharma. This might have increasingly negative impact on the sector and especially on Pfizer. Should that be the case, I’ll probably moderately increase my exposure along the way. Long term these companies provide vital products and – I hope – know how to handle possible litigation in the short term.

Recent Buy: Kesko Oyj (B series)

JP

Partial dividend re-investment and partial injection of fresh capital as Kemira paid dividends recently. This money was used to buy additional 25 shares of Kesko Oyj for 19,03 EUR per share. As anticipated before, this was one of the two planned additions to round the position up to even 300 shares. Identical purchase of additional 25 shares is in the books for December.

Recent Buy: Kesko Oyj (B series)

JP

Dividend re-investment time as both Kesko and Fortum paid dividends this month. Kesko was down today so I bought additional 20 shares for 17,73 EUR per share. This brings my total in 250 shares and right now 300 shares seems like sensible target. I’ll likely nibble remaining 50 shares during next few months.

Recent Buy: Bristol-Myers Squibb

JP

Dividend re-investment time with additional 25 shares of Bristol-Myers Squibb bought for 51,60 USD per share. Original goal was to build a modest position of 100 shares and that has now been completed. Might still slowly increase the position together with Pfizer and Medtronic positions but that remains to be seen. All of these are likely funded with dividends only unless there’s significant market correction.

Q3/2024 Results

JP

Third quarter is over and performance has been surprisingly good considering the mess we are in. US elections are approaching, middle east is middle easting and Finnish economy is performing consistently – pretty badly but consistently. Considering everything stocks have performed incredibly well. My main focus is on dividend income which does not fluctuate with stock prices, therefore there weren’t any major surprises. Dividend income during the quarter was 1527,64 EUR before taxes and when converted to euros at the time writing. Fourth quarter will be interesting one and personally I see potential for significant correction. Not that it matters much as I intend to buy consistently mainly focusing on dividend reinvestments and small injections of fresh capital. Otherwise I’ll let cash position to build up until we either see a major correction or cash position reaches maximum size.

Recent Buy: Kesko Oyj (B series)

JP

Once again a boring maintenance purchase in the form of 20 shares of Kesko Oyj (B series) bought for 18,365 EUR per share. There’s not much to say about this as everything has been said before with similar purchases. Slightly disappointing that I seem to have missed the boat on the cheaper valuations but let’s see what happens in coming months. I’ll likely nibble my way up to 300 shares unless valuation shoots up unexpectedly.